|
Patent landscape, scope, and claims: |
Executive summary
US Patent 9,717,750 is a US method-of-treatment/inclusion patent for intrathecal bolus administration of a highly specific SMN2 exon 7–splicing antisense oligonucleotide defined by: 18 linked nucleosides, SEQ ID NO: 1 base sequence, phosphorothioate internucleoside linkages, and 2′-MOE nucleosides. The claim scope tracks the clinical pharmacology and biomarker mechanism for SMA by requiring exon 7 inclusion (and corresponding SMN2 exon 7 amino-acid inclusion in motoneurons) as an outcome, with dose and timing sub-clauses that cover pediatric and early infant initiation, including within days to months of birth. The enforceable surface is concentrated in US-prescribed dosing regimens and route, creating product-entry and launch sequencing risk for generics/biosimilar-like competitors that rely on substantially different oligonucleotide chemistry, dosing route, or claim-specific regimen endpoints.
US Patent 9,717,750 scope: what exact antisense oligonucleotide and method features are claimed?
At its core, the patent claims a method that combines (i) an antisense oligonucleotide structural definition and (ii) a clinical/biological result plus (iii) route/form (bolus intrathecal injection) and (iv) SMA patient class (type II, type III, and genetic SMN1 loss scenarios).
Core technical claim elements (common across most independent methods)
Across claims 1, 11, 21, 25, and 34, the patent requires all of the following:
- Route and administration form:
- “bolus injection into the intrathecal space” of the human subject.
- Target population:
- SMA contexts including type II (claim 1), type III (claim 11), and genetic/functional-deficiency situations driven by loss of both functional SMN1 copies (claim 21) or mutations causing SMN protein deficiency (claim 25).
- A broad treating SMA catch-all is also present (claim 34).
- Antisense compound composition (hard structural lock-in):
- 18 linked nucleosides
- SEQ ID NO: 1 nucleobase sequence
- phosphorothioate internucleoside linkages
- 2′-MOE nucleosides
- Biological/clinical outcome requirement:
- Claims 1 and 11 use the functional standard “ameliorates at least one symptom of SMA”.
- Claims 21, 25, and 34 hinge on increasing exon 7 inclusion in SMN2 mRNA transcripts.
- Claims 3 and 9 (and counterparts in the type III family) add a motoneuron-level corollary: inclusion of exon 7 amino acids in SMN2 polypeptide in motoneurons is increased.
How outcome language tightens infringement risk
The independent method claims are drafted so that “infringement” is tied to the pharmacodynamic effect (exon 7 inclusion increase, and/or symptom amelioration). Competitors must therefore manage two infringement axes:
- Structural identity: whether their oligonucleotide is within the rigid definition (18-mer, SEQ ID NO: 1, 2′-MOE, phosphorothioate).
- Functional endpoint: whether their administered regimen produces the claimed exon 7 inclusion increase and related motoneuron protein inclusion.
In practice, the “exon 7 inclusion” outcome is measured and expected for SMN2 splicing modulator therapies using the same mechanism. That makes this patent’s claims highly aligned with observed biomarker activity for the labeled mechanism class.
Patient-category drafting is intentionally broad, but not unlimited
Claim 1 covers type II; claim 11 covers type III. Claims 21 and 25 are genetic subclasses defined by SMN1 loss and functional deficiency. Claim 34 covers treating SMA without specifying a type, but still carries the mechanistic exon 7 inclusion requirement.
That creates a “stack” of alternative infringement theories:
- by disease type (II or III), and/or
- by genotype (loss of functional SMN1), and/or
- by clinical labeling objective (treat SMA) coupled to exon 7 inclusion biology.
What do dependent claims add: dosage amounts, unit range, and age/timing windows?
Dependent claims narrow the method to particular dose and start-time windows. The patent’s enforceable footprint is therefore also tied to how a competitor designs its US clinical protocol.
Dose constraints (claims 2, 12, 23, 26, 3, 13 not present as dose; dosage appears in multiple dependent sets)
These claims define both a mg/kg range and a fixed mg range:
- 0.01 to 10 mg/kg (claims 2, 12, 23, 26)
- 5 mg to 20 mg (claims 4, 14, 24, 27)
First-dose timing and initiation windows (claims 5-8, 15-20, 28-33, 37-42)
The patent repeatedly claims pediatric initiation:
- Within one week of birth (claims 28, 37)
- Within one month of birth (claims 29, 38)
- Within three months of birth (claims 30, 39)
- Within six months of birth (claims 31, 40)
- At age 1 to 2 years (claims 5, 7, 15, 17, 32, 41)
- At age 1 to 15 years (claims 6, 8, 16, 18, 33, 42)
This is not merely a “pediatric use” add-on. It creates multiple dependent hooks that can be asserted depending on how the accused product’s US label and real-world dosing are executed.
What is uniquely covered for exon 7 inclusion outcomes
Claims 21, 25, and 34 anchor on increasing exon 7 inclusion in SMN2 mRNA. The patent further includes:
- Genetic identification by test (claim 22):
- Subject is identified by genetic test as having SMN1 mutation.
- Functional SMN protein deficiency linkage (claim 25):
- Mutations leading to functional SMN protein deficiency.
These provisions can matter in infringement theory because they map to diagnostic workflows used to select eligible patients for SMN2 splicing therapy.
How much of the claim set is “route and form” versus “mechanism and biomarker”?
A meaningful allocation emerges:
- Route/form is strict in all independent-method claims:
- bolus intrathecal injection.
- Mechanism is strict through the antisense structural definition and endpoint:
- structural definition: 18-mer, SEQ ID NO: 1, 2′-MOE, phosphorothioate
- outcome: symptom amelioration and/or exon 7 inclusion increase, plus motoneuron exon 7 amino-acid inclusion.
Thus, the patent’s “design-around” options are constrained unless a competitor can change one of:
- route (not intrathecal bolus),
- form (not bolus injection),
- chemistry/sequence (not the exact 18-mer SEQ ID NO: 1 with 2′-MOE and phosphorothioate linkages),
- endpoint (not increasing exon 7 inclusion in mRNA transcripts, which is not credible if using the same splicing-modulating core).
What patents likely overlap or compete with US 9,717,750 in SMA antisense splicing landscapes?
Given the claim architecture (18-mer, 2′-MOE, phosphorothioate, SEQ ID NO: 1, intrathecal bolus, exon 7 splicing outcome), the US estate is expected to sit adjacent to three common IP clusters in SMA antisense therapeutics:
- Molecular definition patents
- Specific oligonucleotide sequences and chemistries (length, backbone chemistry, sugar modification).
- Formulation/manufacturing and dosing device patents
- Delivery presentation for intrathecal administration.
- Method-of-use and regimen patents
- Patient selection, dose regimen, and outcome biomarkers (exon 7 inclusion; SMN protein expression).
The specific question is: how strongly this patent blocks alternatives that are “mechanistically similar” but “chemically different.”
- If a competitor uses a different sequence or different backbone chemistry (not 2′-MOE/phosphorothioate as claimed), infringement likely fails on the structural element.
- If a competitor uses the same general mechanism but different nucleoside chemistry or length, infringement can still be contested on “sequence/chemistry” rather than on route or timing.
- If a competitor uses an alternative SMA oligonucleotide that still modulates exon 7, they may still avoid this patent if the oligo is not within SEQ ID NO: 1 and the chemistry is outside the claimed structure.
When does US 9,717,750 lose exclusivity? How do expiry and pediatric timing interact?
No expiration date, priority date, or term adjustment data was provided in the prompt text. Without the filing/priority/USPTO data for US 9,717,750, a definitive expiry computation cannot be produced from the claim text alone.
What “design-around” strategies are implied by the claim wording of US 9,717,750?
The most direct, claim-literal design-around levers are:
1) Change the oligonucleotide definition
- Different nucleoside count (not 18 linked nucleosides)
- Different SEQ ID NO: 1 sequence
- Different nucleoside type (not 2′-MOE)
- Different internucleoside linkage (not phosphorothioate)
This is the highest-probability route to avoid literal infringement if the competing product is not within the defined structure.
2) Change the route or “bolus intrathecal injection” feature
If a competitor uses a non-intrathecal route or a non-bolus administration format, it may avoid the literal recitation. However, this is clinically difficult for SMN2 splicing antisense agents that are typically delivered intrathecally; the patent’s language is therefore a meaningful guardrail.
3) Manage the claimed dose regimen windows
Dependent claims recite discrete dosing and timing windows. A competitor that uses different dosing ranges or initiation windows could seek to avoid dependent-claim infringement. Independent claims 1/11/21/25/34 remain available, so dosing-window changes may not fully eliminate risk unless they also avoid the core structural and endpoint elements.
How strong is the patent estate likely to be around the claimed biomarker (exon 7 inclusion) and regimen?
Strength drivers from the claim set itself:
- Strict structural oligo identity: 18-mer, SEQ ID NO: 1, 2′-MOE, phosphorothioate.
- Strict route/form: intrathecal bolus injection.
- Strict pharmacodynamic outcome:
- increasing exon 7 inclusion in SMN2 mRNA transcripts
- increasing exon 7 amino-acid inclusion in SMN2 polypeptide in motoneurons
- symptom amelioration (for type II and type III independent claims)
Weakness drivers are not inferable from the claim list alone; infringement/invalidity depends on prosecution history, prior art sequences, obviousness/enablement issues, and whether the claimed “outcome” is treated as a functional result tied to disclosed examples.
What generic entry risks exist for an intrathecal SMA antisense competitor under the US claim structure?
For a competitor pursuing an “enter-by-infringement-avoidance” strategy:
- Generic-style changes that do not alter the exact oligo structure will likely preserve exon 7 inclusion and the intrathecal bolus endpoint, preserving infringement risk.
- If the competitor attempts to use a different antisense sequence or different nucleoside chemistry, then risk shifts from exon 7 inclusion to whether the oligo falls within the SEQ ID NO: 1 + 2′-MOE + phosphorothioate + 18-mer definition.
The patent is therefore best read as a chemistry-and-regimen-gated method barrier rather than a broad “any SMA treatment increases exon 7” barrier.
What litigation, settlements, or Orange Book status apply to US 9,717,750?
No litigation docket numbers, settlement agreements, or FDA Orange Book listings were provided in the prompt text. Without those inputs, this analysis cannot map claim scope to specific Paragraph IV challenges or Orange Book actives.
Key claim chart (US 9,717,750)
| Claim |
Patient scope |
Administration |
Oligonucleotide definition |
Outcome/biomarker requirement |
Regimen limits added |
| 1 |
Type II SMA |
Intrathecal bolus injection |
18 linked nucleosides; SEQ ID NO: 1; phosphorothioate linkages; 2′-MOE |
Ameliorates at least one SMA symptom |
Dependent: dose mg/kg, dose mg |
| 2 |
Type II |
Intrathecal bolus |
As above |
As above |
0.01–10 mg/kg |
| 3 |
Type II |
Intrathecal bolus |
As above |
Exon 7 inclusion in SMN2 mRNA in motoneurons increased |
None stated in claim 3 text |
| 4 |
Type II |
Intrathecal bolus |
As above |
As above |
5–20 mg |
| 5-8 |
Type II |
As above |
As above |
As above |
First dose age windows: 1–2 and 1–15 years (different dependent groupings) |
| 11 |
Type III SMA |
Intrathecal bolus |
As above |
Ameliorates at least one SMA symptom |
Dependent: dose mg/kg, dose mg |
| 12-14 |
Type III |
As above |
As above |
As above |
0.01–10 mg/kg; 5–20 mg |
| 15-18 |
Type III |
As above |
As above |
As above |
First dose age windows: 1–2 and 1–15 years |
| 19-20 |
Type III |
As above |
As above |
Exon 7 amino-acid inclusion in motoneuron SMN2 increased |
None stated beyond the exon 7 protein result |
| 21 |
SMN1 functional loss (both functional copies) |
Intrathecal bolus |
As above |
Increase exon 7 inclusion in SMN2 mRNA transcripts |
Dependent: genetic test; dose mg/kg; dose mg |
| 22 |
SMN1 mutation identified by genetic test |
As above |
As above |
As above |
Adds genetic-test identification |
| 23-24 |
SMN1 functional loss |
As above |
As above |
As above |
0.01–10 mg/kg; 5–20 mg |
| 25 |
SMN1 mutations causing functional SMN protein deficiency |
Intrathecal bolus |
As above |
Increase exon 7 inclusion in SMN2 mRNA transcripts |
Dependent: dose mg/kg, dose mg, start timing |
| 26-27 |
As above |
As above |
As above |
As above |
0.01–10 mg/kg; 5–20 mg |
| 28-31 |
As above |
As above |
As above |
As above |
First dose within 1 week / 1 month / 3 months / 6 months of birth |
| 32-33 |
As above |
As above |
As above |
As above |
First dose at 1–2 or 1–15 years |
| 34 |
Treating SMA (broad) |
Intrathecal bolus |
As above |
Increase exon 7 inclusion in SMN2 mRNA transcripts |
Dependent: dose, first dose windows |
| 35-36 |
Treating SMA |
As above |
As above |
As above |
0.01–10 mg/kg; 5–20 mg |
| 37-40 |
Treating SMA |
As above |
As above |
As above |
First dose within 1 week / 1 month / 3 months / 6 months |
| 41-42 |
Treating SMA |
As above |
As above |
As above |
First dose at 1–2 or 1–15 years |
Key Takeaways
- US 9,717,750 claims intrathecal bolus delivery of a precisely defined 18-mer antisense oligonucleotide (SEQ ID NO: 1; 2′-MOE; phosphorothioate linkages).
- Independent claims target SMA type II, SMA type III, genetically defined SMN1 loss/deficiency, and treatment of SMA.
- The claim set is anchored to biomarker outcome: increased exon 7 inclusion in SMN2 mRNA transcripts, plus motoneuron exon 7 amino-acid inclusion in selected claims.
- Dependent claims materially expand enforceability via dose ranges (mg/kg and mg) and initiation timing windows, including dosing within one week to six months of birth and ages 1–2 and 1–15 years.
- Design-around risk concentrates on whether a competitor’s oligonucleotide is outside the rigid sequence/chemistry and whether administration deviates from intrathecal bolus.
FAQs
-
Does US 9,717,750 require proof of exon 7 inclusion in SMN2 mRNA to establish infringement?
In claims 21, 25, and 34 the method outcome is explicitly exon 7 inclusion increase in SMN2 mRNA transcripts; in claims 1 and 11 the method is tied to symptom amelioration.
-
Can a competitor avoid infringement by changing the patient type from Type II to Type I?
Not fully. The genetic SMN1-loss and treatment-of-SMA independent claims remain, and each still requires exon 7 inclusion as claimed (for those independent claims).
-
Do the dependent dose and age-window clauses limit or expand infringement exposure?
They create additional, narrower claim hooks tied to specific dose ranges and first-dose timing, which can support infringement theories even when core independent elements are contested.
-
Is the route “intrathecal bolus injection” a key claim barrier for administration variants?
Yes. The claims explicitly require bolus injection into the intrathecal space, so any materially different delivery route or non-bolus format can target avoidance of the recited administration step.
-
Is the genetic test language in claim 22 required for all infringement theories?
No. Claim 22 is a dependent feature within the genetic subclass (claim 21). Independent claim coverage for SMN1 loss-based methods exists without the genetic-test limitation.
References
- Provided in the prompt: US Drug Patent 9,717,750 claims text.
More… ↓
⤷ Start Trial
|
